Both our results and GWAS showed that multiple variants of IL23R were significantly associated with IBD and suggested that blocking the IL-23 signaling pathway may be a reasonable treatment strategy for IBD (Duerr et al. 2006). This evidence concerns the gene IL37 and inflammatory bowel disease.